Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
Grima AA, Kwong JC, Richard L, Reid J, Raphael J, Basta NE, Carignan A, Top KA, Brousseau N, Blanchette PS, Sundaram ME; Canadian Immunization Research Network (CIRN) Investigators. Grima AA, et al. Among authors: brousseau n. Vaccine. 2024 Mar 7;42(7):1498-1505. doi: 10.1016/j.vaccine.2024.01.023. Epub 2024 Feb 9. Vaccine. 2024. PMID: 38341288 Free article.
Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada.
Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, Brousseau N, Drolet M, Ouakki M, Sauvageau C, Barkati S, Fortin É, Carignan A, De Wals P, Skowronski DM, De Serres G. Carazo S, et al. Among authors: brousseau n. Clin Infect Dis. 2022 Aug 24;75(1):e805-e813. doi: 10.1093/cid/ciab739. Clin Infect Dis. 2022. PMID: 34460902 Free PMC article.
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.
Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G, Galanis E, Fjell CD, Sbihi H, Fortin E, Barkati S, Sauvageau C, Naus M, Patrick DM, Henry B, Hoang LMN, De Wals P, Garenc C, Carignan A, Drolet M, Jassem AN, Sadarangani M, Brisson M, Krajden M, De Serres G. Skowronski DM, et al. Among authors: brousseau n. Clin Infect Dis. 2022 Nov 30;75(11):1980-1992. doi: 10.1093/cid/ciac290. Clin Infect Dis. 2022. PMID: 35438175 Free PMC article.
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G. Carazo S, et al. Among authors: brousseau n. Lancet Infect Dis. 2023 Jan;23(1):45-55. doi: 10.1016/S1473-3099(22)00578-3. Epub 2022 Sep 21. Lancet Infect Dis. 2023. PMID: 36152671 Free PMC article.
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.
Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G. Carazo S, et al. Among authors: brousseau n. JAMA Netw Open. 2022 Oct 3;5(10):e2236670. doi: 10.1001/jamanetworkopen.2022.36670. JAMA Netw Open. 2022. PMID: 36239934 Free PMC article.
59 results